Walleye Capital LLC Arbutus Biopharma Corp Transaction History

Walleye Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.42 - $3.98 $416,794 - $685,471	-172,229 Closed	0 $0
Q4 2021 Mar 03, 2022	SELL	$3.11 - $4.61 $182,892 - $271,104	-58,808 Reduced 25.45%	172,229 $669,000
Q3 2021 Nov 15, 2021	BUY	$2.65 - $4.62 $612,248 - $1.07 Million	231,037 New	231,037 $991,000
Q4 2019 Feb 14, 2020	SELL	$0.87 - $2.89 $19,637 - $65,233	-22,572 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$1.34 - $2.4 $30,246 - $54,172	22,572 New	22,572 $34,000

Q1 2019 May 15, 2019	SELL	$3.41 - $4.57 $46,352 - $62,120	-13,593 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$7.85 - $12.35 $106,705 - $167,873	13,593 New	13,593 $128,000

130

82.2M

4.82M

546K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $489M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.